$FBIO

Fortress Biotech, Inc. (FBIO): Submission of Matters to a Vote of Security Holders

Fortress Biotech, Inc. (FBIO) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Fortress Biotech, Inc._June 17, 2026 0001429260 false 0001429260 us-gaap:CommonStockMember 2026-06-17 2026-06-17 0001429260 fbio:SeriesCumulativeRedeemablePerpetualPreferredStockMember 2026-06-17 2026-06-17 0001429260 2026-06-17 2026-06-17 ​ ​ UNITED STATES SECURITIES AND EXCHANG

Original reporting
Published Jun 23, 2026, 8:05 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 23, 2026, 8:06 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefCorporate actions
Primary signal
$FBIO
Neutral
high confidence
Mentioned
$FBIO
Relevance
6/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$FBIONeutralLow
01

Why it matters

The disclosure confirms the election of seven directors and ratification of KPMG LLP as independent registered public accounting firm for the year ending Dec. 31, 2026; no new guidance, trial results, financing, or enforcement actions are included.

02

Market read

Primarily administrative governance reporting; unlikely to drive trading decisions without additional contested items or material corporate actions.

03

What to watch

The 8-K references the definitive proxy statement for details, but this excerpt contains only vote counts and does not specify any director changes, compensation, or auditor-related issues beyond ratification.

Relevance 6/10Novelty 2/10Timing: filed June 23, 2026 after June 17 annual meeting vote results

Background

This is an SEC Form 8-K (Item 5.07) reporting matters submitted to a vote of security holders at Fortress Biotech’s June 17, 2026 annual meeting.

Company-level read

Ticker impact

$FBIONeutralHigh confidence
Context

Fortress Biotech filed an 8-K confirming June 17, 2026 annual meeting votes: seven directors elected and KPMG ratified for 2026.

Expected impact

Limited near-term impact; any reaction likely muted unless investors were focused on board/accounting outcomes.

Evidence & confidence

The filing reports vote tallies and ratification of the independent auditor, which are typically non-material to fundamentals absent additional context.

Market effects

Minimal; governance/auditor ratification does not change biotech sector risk or read-across.

Minimal; Nasdaq-listed small/mid-cap governance update only.

Minimal; no cross-border transaction or regulatory action mentioned.

Counterpoint

If there were contested governance issues, the vote outcome could reduce uncertainty; however, the filing provides no dispute or change in control details.

Key entities

  • Fortress Biotech, Inc.

    Nasdaq-listed registrant reporting annual meeting vote results on Form 8-K.

  • KPMG LLP

    Independent registered public accounting firm ratified for 2026.

Related articles

$RIOMedAI 8/10

Australia’s Federal and NSW governments agreed on a $2.5 billion package to keep Rio Tinto’s Tomago aluminium smelter operating

Australia’s Federal and NSW governments agreed on a $2.5 billion package to keep Rio Tinto’s Tomago aluminium smelter operating. Rio Tinto said it would shut the Hunter Valley smelter at end-2028 without an affordable electricity deal. The deal includes up to $1.225 billion from NSW, supports new power generation (including Snowy Hydro), and runs to 2039 with profit sharing tied to sustained high aluminium prices.

Med

AI nuclear power firm Fermi finally has a new CEO

Fermi, an AI nuclear power company, named Lee McIntire as CEO more than three months after firing co-founder Toby Neugebauer. Fermi said McIntire previously led CH2M Hill and TerraPower. The firm is developing Project Matador in Amarillo, Texas, and said it signed TensorWave as its first binding customer lease. Fermi stock rose nearly 23% since Monday.

$NVDAMed

Nvidia's AI revolution will be securitized

Nvidia said it plans to raise about $500 billion to finance AI infrastructure buildouts with six North American investment firms: Apollo, BlackRock, Blackstone, Brookfield, Goldman Sachs, and KKR. The firms may use GPU securitizations to spread exposure across investors. Nvidia may provide residual-value support of up to 25%, according to the company.

$FAMed

First Advantage shares fall 8% after Silver Lake secondary share offering

First Advantage (NASDAQ:FA) shares fell about 8% after Silver Lake-affiliated funds announced a secondary offering of 12.5 million FA shares. Bloomberg reported a marketing range of $22.20 to $23.59 versus Monday’s $23.59 close. The company will not sell shares or receive proceeds. J.P. Morgan is underwriter; a 30-day lock-up applies to the seller, with some shares to limited partners.

$AREMed

Alexandria Real Estate Sets 7.25% Interest Through Feb. 15, 2032

Alexandria Real Estate Equities (NYSE: ARE) priced a $1.0 billion public offering of 7.250% Series A fixed-to-fixed reset rate junior subordinated notes due 2057 at 100% of principal. Interest is 7.250% until Feb. 15, 2032, then resets to the 5-year U.S. Treasury plus 2.889%, with a 7.250% floor. Closing expected around Aug. 21, 2026; proceeds for general corporate purposes.